Cargando…
Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak
PURPOSE: The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499926/ https://www.ncbi.nlm.nih.gov/pubmed/32946004 http://dx.doi.org/10.1007/s10792-020-01593-0 |
_version_ | 1783583763478872064 |
---|---|
author | Nicolò, Massimo Ferro Desideri, Lorenzo Bassetti, Matteo Traverso, Carlo Enrico |
author_facet | Nicolò, Massimo Ferro Desideri, Lorenzo Bassetti, Matteo Traverso, Carlo Enrico |
author_sort | Nicolò, Massimo |
collection | PubMed |
description | PURPOSE: The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ. METHODS: A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020. RESULTS: Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future. CONCLUSION: A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection. |
format | Online Article Text |
id | pubmed-7499926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-74999262020-09-21 Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak Nicolò, Massimo Ferro Desideri, Lorenzo Bassetti, Matteo Traverso, Carlo Enrico Int Ophthalmol Review PURPOSE: The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ. METHODS: A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020. RESULTS: Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future. CONCLUSION: A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection. Springer Netherlands 2020-09-18 2021 /pmc/articles/PMC7499926/ /pubmed/32946004 http://dx.doi.org/10.1007/s10792-020-01593-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Nicolò, Massimo Ferro Desideri, Lorenzo Bassetti, Matteo Traverso, Carlo Enrico Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title_full | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title_fullStr | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title_full_unstemmed | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title_short | Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak |
title_sort | hydroxychloroquine and chloroquine retinal safety concerns during covid-19 outbreak |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499926/ https://www.ncbi.nlm.nih.gov/pubmed/32946004 http://dx.doi.org/10.1007/s10792-020-01593-0 |
work_keys_str_mv | AT nicolomassimo hydroxychloroquineandchloroquineretinalsafetyconcernsduringcovid19outbreak AT ferrodesiderilorenzo hydroxychloroquineandchloroquineretinalsafetyconcernsduringcovid19outbreak AT bassettimatteo hydroxychloroquineandchloroquineretinalsafetyconcernsduringcovid19outbreak AT traversocarloenrico hydroxychloroquineandchloroquineretinalsafetyconcernsduringcovid19outbreak |